FOSUN PHARMA News

Fosun Pharma to Sell United Family Healthcare

Yahoo Finance12:24 ET

GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.

GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.

Zhitong FinanceMar 16 21:18 ET

Is the breakthrough path all in AI? Chain pharmacies are facing a wave of closures and an era of low profits.

① In 2024, particularly in the second half of the year, chain pharmacies will face a large-scale wave of closures, and leading chain pharmacies will generally enter a low-profit era. ② AI is also being assigned higher expectations in helping pharmacies reduce costs and increase efficiency. ③ Publicly available large models, due to a lack of support from vertical domain data, are still insufficient to support the actual Business Operation of pharmacies.

cls.cnMar 16 02:09 ET

Fosun Pharma Offloads $124m Stake in Hospital Group to Warburg Pincus - Nikkei

InvestingMar 14 12:42 ET

Shanghai Fosun Pharmaceutical (Group)'s Subsidiary PNH Drug Gets NMPA's Nod for Clinical Trials; Shares Rise 4%

MT NewswiresMar 14 03:57 ET

AI and policy are driving forces! Hong Kong pharmaceutical stocks collectively "rebound" with WUXI BIO surging over 14% to lead the Industry.

① What technological breakthroughs have driven the improvement of research and development efficiency in the Biomedical Industry? ② What are the reasons for the leading increase in WuXi's affiliated companies?

cls.cnMar 14 00:35 ET

Fosun Pharma Gets Clinical Trial Approval for Blood Disorder Drug

MT NewswiresMar 13 23:08 ET

Hong Kong stocks are experiencing fluctuations | CRO Concept stocks are warming up. The integration of AI and CXO has entered a new stage. Institutions claim that the external environment for CRO may be improving.

As of the time of writing, the CRO Concept has warmed up, with VIVA BIOTECH (01873) rising by 11.89% to 1.6 HKD; WUXI BIO (02269) increasing by 10.3% to 25.7 HKD; PHARMARON (03759) up by 5.67% to 16.04 HKD; and TIGERMED (03347) climbing by 5.86% to 37.05 HKD.

Zhitong FinanceMar 13 22:47 ET

Announcement highlights | AIA's new business value for the year 2024 increased by 18% year-on-year to 4.712 billion USD, proposing a final dividend of 130.98 Hong Kong cents per share; Weibo's net profit for the fiscal year 2024 decreased by 12.2% year-on

BOC AVIATION's Net income for 2024 increased by about 20%; YUEXIUTRANSPORT's revenue declined year-on-year last year.

cls.cnMar 13 20:22 ET

0.124 billion USD! FOSUN PHARMA and United Family Healthcare "completely part ways" | Quick announcement.

① FOSUN PHARMA's subsidiary plans to sell a 6.6% stake in the symbol company for 0.124 billion USD; ② The relationship between FOSUN PHARMA and Huameijia can be traced back to 2009; ③ After this Trade is completed, FOSUN PHARMA will completely exit Huameijia.

cls.cnMar 13 11:26 ET

Hong Kong Stock Announcement Gold Mining | Weibo-SW released its annual results with a net income of 0.301 billion USD attributable to Weibo shareholders, and the annual operating profit margin reached 28%.

Weibo-SW releases annual performance, with a net income of 0.301 billion dollars attributable to Weibo shareholders, and an annual operating profit margin of 28%; Vison Pharma-B (02561) plans to globally issue 9.9 million shares to introduce cornerstone investors such as Anhui Anke Biotechnology and Yuanfeng...

Zhitong FinanceMar 13 10:57 ET

Express News | Shanghai Fosun Pharma - Unit Got Approval for Clinical Trial of Xh-S003 Capsules From Nmpa China

ReutersMar 13 07:09 ET

FOSUN PHARMA (600196.SH): The holding subsidiary intends to sell Assets to Calcite Gem.

On March 13, Gelonghui reported that FOSUN PHARMA (600196.SH) announced that its controlling subsidiary, FOSUN Industrial, signed a "Share Transfer Agreement" with CalciteGem. FOSUN Industrial intends to transfer 9.4 million shares of common stock, accounting for approximately 6.6% of the total shares of the symbol company as of the date of this announcement (March 13, 2025), to CalciteGem for a cash consideration of 124.08 million US dollars. After the completion of this Trade, the group will no longer ...

Gelonghui FinanceMar 13 05:51 ET

Express News | Shanghai Fosun Pharmaceutical Says Unit Plans to Sell United Family Healthcare Related Asset for $124.1 Mln

ReutersMar 13 05:50 ET

FOSUN PHARMA (600196.SH) subsidiary Xinghao Pengbo has obtained approval for a pharmaceutical clinical trial.

FOSUN PHARMA (600196.SH) announced that its holding subsidiary Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd. (abbreviated as "...")

Zhitong FinanceMar 13 05:41 ET

Shanghai Fosun Pharmaceutical Schedules Board Meeting for Year-End Results

TipRanksMar 13 04:49 ET

FOSUN PHARMA (02196.HK) will hold a Board of Directors meeting on March 25 to approve the annual performance.

Gelonghui, March 13 丨 FOSUN PHARMA (02196.HK) announced that the company will hold a Board of Directors meeting on March 25, 2025, to review and approve the annual performance of the company and its subsidiaries for the year ending December 31, 2024, and to consider the proposal for the payment of a final dividend, if any.

Gelonghui FinanceMar 13 04:38 ET

FOSUN PHARMA: DATE OF BOARD MEETING

HKEXMar 13 04:31 ET · Announcements

Fosun Pharma Unit Gets China Nod to Register Foritinib Succinate Capsules

MT NewswiresMar 6 23:42 ET

National People's Congress representative, Zhao Jing of Shandong Buchang Pharmaceuticals: "The 'AI+' is reaching a critical point of explosion. It is recommended to utilize AI to empower the inheritance and innovation of Traditional Chinese Medicine | Two

① Zhao Jing, a representative of the National People's Congress and Vice Director of Shandong Buchang Pharmaceuticals, brought the proposal "Utilizing AI to Empower the Inheritance and Innovation of Traditional Chinese Medicine and Build a New Pattern of Development for Traditional Chinese Medicine with 'Asia Vets + Technology'" to this year's Two Sessions, aiming to promote the intelligent upgrade of the Traditional Chinese Medicine industry through AI technology. ② Zhao Jing stated that the development of large models like DeepSeek has indeed pushed the integration of Traditional Chinese Medicine and AI to a critical point of explosion.

cls.cnMar 6 20:48 ET